Lifeboat Foundation

A team of mechanical engineers at Nanyang Technological University in Singapore has found a way to electronically control cockroaches without injuring them. In their paper published in the journal npj Flexible Electronics, the group describes the new technology they used to remotely control the cockroaches and the benefits of doing so.

Prior research teams have created a variety of cyborg cockroaches, but they all had one feature in common—they all involved attaching probes to the insect’s nervous system—procedures that led to damage to the insect, and likely some degree of pain.

Continue reading “A non-invasive way to turn a cockroach into a cyborg” »

Blood plasma from young donors treating age-related conditions (RAADfest 2023)

Just about everyone may want to look and feel younger and healthier, but multimillion-dollar investments and broccoli smoothies are not for everyone. Still, that doesn’t mean the less hardcore among us are out of luck if we’re hoping to turn back the clock on our brain health.

New research by a team of psychologists uncovered a simple way just about anyone can get their brain working like it’s decades younger.

You probably don’t need science to tell you this, but people’s cognitive acuity generally starts to level off in their 30s and 40s before declining more markedly in their 60s. Most of us write our slower responses and memory lapses off to the unavoidable indignities of aging. But what if they were just the adult equivalent of the “summer slide” that affects kids, a pair of researchers wanted to know.

Though drug developers have achieved some progress in treating Alzheimer’s disease with medicines that reduce amyloid-beta protein, other problems of the disease, including inflammation, continue unchecked. In a new study, scientists at The Picower Institute for Learning and Memory at MIT describe a candidate drug that in human cell cultures and Alzheimer’s mouse models reduced inflammation and improved memory.

The target of the new “A11” molecule is a genetic transcription factor called PU.1. Prior research has shown that amid Alzheimer’s disease, PU.1 becomes an overzealous director of inflammatory gene expression in the brain’s microglia immune cells. A11 suppresses this problematic PU.1 activity, the new research shows, by recruiting other proteins that repress the inflammatory genes PU.1 works to express. But because A11 concentrates mostly in the brain and does not reduce PU.1 levels, it does not appear to disrupt PU.1’s other job, which is to ensure the production of a wide variety of blood cells.

“Inflammation is a major component of Alzheimer’s disease pathology that has been especially hard to treat,” says study senior author Li-Huei Tsai, Picower Professor of Neuroscience at MIT and director of The Picower Institute and MIT’s Aging Brain Initiative. “This preclinical study demonstrates that A11 reduces inflammation in human microglia-like cells, as well as in multiple mouse models of Alzheimer’s disease, and significantly improves cognition in the mice. We believe A11 therefore merits further development and testing.”

As we age, our muscles and other tissues break down in much the same way as degenerative diseases progress. What we learn from studying degenerative diseases such as muscular dystrophy could help researchers develop new interventions to fight common age-related ailments and chronic illnesses.

With help from NIA, biotechnology company Juvena Therapeutics has begun unlocking the secrets of proteins for regenerative medicine. Juvena scientists are using a form of muscular dystrophy — myotonic dystrophy type 1 (DM-1) — as a model to sift through proteins that are produced by the body’s stem cells. These cells have the potential to become any type of cell in the body, from liver tissue to skin cells. The goal is to find proteins that encourage tissue growth and repair, ultimately designing new drugs to prevent and treat degenerative diseases like DM-1. As part of this process, Juvena hopes to learn more about how to reduce the effects of aging on muscles and other tissues, too.

A new biotech trying to establish itself can feel isolated from the larger scientific community. For example, Juvena is unable to submit findings for publication before taking care of intellectual property protections. But NIH’s peer-review process offered confidential, scientifically rigorous feedback to fill that critical gap, and the NIA Small Business Programs staff offered helpful advice.

Continue reading “Funded Small Business Spotlight: Juvena Therapeutics Unlocking the Secrets of Tissue Regeneration” »

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
Oral Microbiome: https://www.bristlehealth.com/?ref=michaellustgarten.
Enter Code: ConquerAging.

Continue reading “Albumin, CRP, and Creatinine: Better Markers Of Longevity Than Lipoproteins And Glycemic Status” »

A fortnightly meetup for the Transhumanism movement in Sydney to discuss the latest developments in emerging technology and product roadmap.

Insights into healing and aging were discovered by National Institutes of Health researchers and their collaborators, who studied how a tiny sea creature regenerates an entire new body from only its mouth. The researchers sequenced RNA from Hydractinia symbiolongicarpus, a small, tube-shaped animal that lives on the shells of hermit crabs. Just as the Hydractinia were beginning to regenerate new bodies, the researchers detected a molecular signature associated with the biological process of aging, also known as senescence. According to the study published in Cell Reports, Hydractinia demonstrates that the fundamental biological processes of healing and aging are intertwined, providing new perspective on how aging evolved.

https://www.nih.gov/news-events/news-releases/scientists-dis…a-creature

Continue reading “Scientists discover clues to aging and healing from a squishy sea creature” »

Discovering And Developing Medicines To Keep You Biologically Young — Dr. Marco Quarta, Ph.D. — Co-Founder and CEO, Rubedo Life Sciences; CEO, Phaedon Institute.

Dr. Marco Quarta, Ph.D. is Co-Founder and CEO of Rubedo Life Sciences (https://www.rubedolife.com/), a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. The company’s proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders.

Continue reading “Dr. Marco Quarta, Ph.D. — Co-Founder and CEO — Rubedo Life Sciences; CEO, The Phaedon Institute” »